
Profitability, historical returns, and peer comparisons.
According to CStone Pharmaceuticals’s latest financial reports and current stock price. The company's current ROE is -43.54%. This represents a change of 46.90% compared to the average of -29.64% of the last 4 quarters.
The mean historical ROE of CStone Pharmaceuticals over the last ten years is -111.62%. The current -43.54% ROE has changed -61.00% with respect to the historical average. Over the past ten years (40 quarters), CSPHF's ROE was at its highest in in the June 2024 quarter at 3.36%. The ROE was at its lowest in in the December 2018 quarter at -244.79%.
Average
-111.62%
Median
-76.42%
Minimum
-338.67%
Maximum
-25.07%
Discovering the peaks and valleys of CStone Pharmaceuticals ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 367.42%
Maximum Annual ROE = -25.07%
Minimum Annual Increase = -72.53%
Minimum Annual ROE = -338.67%
| Year | ROE | Change |
|---|---|---|
| 2025 | -70.82% | 182.55% |
| 2024 | -25.07% | -68.82% |
| 2023 | -80.39% | -59.99% |
| 2022 | -200.90% | 26.29% |
| 2021 | -159.08% | 285.27% |
| 2020 | -41.29% | -55.61% |
| 2019 | -93.02% | -72.53% |
| 2018 | -338.67% | 367.42% |
| 2017 | -72.46% | 109.83% |
The current ROE of CStone Pharmaceuticals (CSPHF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-58.76%
5-year avg
-107.25%
10-year avg
-111.62%
CStone Pharmaceuticals’s ROE is less than HUTCHMED (China) Limited (1.43%), greater than Zai Lab Limited (-27.40%), greater than ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (-32.32%), less than Shanghai Henlius Biotech, Inc. (20.41%), greater than Mabwell-b (-205.41%), less than InnoCare Pharma Limited (17.47%), less than Edding Genor Group Holdings Limited (10.99%), less than Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (2.43%), greater than Nanjing Leads Biolabs Co Ltd (-23.34%), less than Antengene Corporation Limited (6.51%),
| Company | ROE | Market cap |
|---|---|---|
| 1.43% | $19.92B | |
| -27.40% | $22.56B | |
| -32.32% | $1.21B | |
| 20.41% | $27.67B | |
| -205.41% | $10.28B | |
| 17.47% | $18.22B | |
| 10.99% | $3.15B | |
| 2.43% | $110.38B | |
| -23.34% | $7.45B | |
| 6.51% | $1.80B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CStone Pharmaceuticals using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CStone Pharmaceuticals or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is CStone Pharmaceuticals's ROE?
How is the ROE calculated for CStone Pharmaceuticals (CSPHF)?
What is the highest ROE for CStone Pharmaceuticals (CSPHF)?
What is the 3-year average ROE for CStone Pharmaceuticals (CSPHF)?
What is the 5-year average ROE for CStone Pharmaceuticals (CSPHF)?
How does the current ROE for CStone Pharmaceuticals (CSPHF) compare to its historical average?